AWM
REGN icon

Abound Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Abound Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32K Sell
51
-13
-20% -$8.85K 0.01% 293
2026
Q1 		$49.3K Buy
64
+8
+14% +$6.13K 0.01% 249
2025
Q4 		$43.3K Sell
56
-3
-5% -$2.04K 0.01% 250
2025
Q3 		$32.9K Buy
59
+14
+31% +$7.92K 0.01% 277
2025
Q2 		$23.5K Buy
45
+9
+25% +$5.02K 0.01% 305
2025
Q1 		$23K Sell
36
-3
-8% -$2.06K 0.01% 276
2024
Q4 		$28K Sell
39
-2
-5% -$1.68K 0.01% 234
2024
Q3 		$43.2K Buy
41
+4
+11% +$4.45K 0.01% 194
2024
Q2 		$39.3K Buy
37
+2
+6% +$1.94K 0.01% 178
2024
Q1 		$33.8K Buy
35
+3
+9% +$2.85K 0.01% 184
2023
Q4 		$27.8K Buy
32
+7
+28% +$5.76K 0.01% 209
2023
Q3 		$20.6K Buy
25
+6
+32% +$4.71K 0.01% 216
2023
Q2 		$13.4K Buy
19
+5
+36% +$3.85K 0.01% 288
2023
Q1 		$11.5K Buy
14
+4
+40% +$3.02K 0.01% 272
2022
Q4 		$7.21K Sell
10
-6
-38% -$4.43K ﹤0.01% 304
2022
Q3 		$11K Buy
+16
New +$10.1K 0.01% 262

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Abound Wealth Management's REGN Position: Q2 2026 in Review

Abound Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, selling an estimated $8.85K and leaving 51 shares worth $32K. The position accounts for 0.01% of the portfolio, ranked #293.

Abound Wealth Management first reported a position in REGN in Q3 2022 and has held it in 16 quarters since. The position peaked at $49.3K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Abound Wealth Management held 51 shares of Regeneron Pharmaceuticals worth $32K as of Q2 2026.
  • Abound Wealth Management sold 13 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $8.85K.
  • Regeneron Pharmaceuticals made up 0.01% of Abound Wealth Management's portfolio in Q2 2026, its #293 holding.
  • Abound Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's Regeneron Pharmaceuticals position peaked at $49.3K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.